Last updated on February 2017

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine


Brief description of study

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Detailed Study Description

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.

Clinical Study Identifier: TX147302

Contact Investigators or Research Sites near you

Start Over

Sherry Harlan

University of South Florida - Morsani Center for Advanced Healthcare
Tampa, FL USA
  Connect »